DOR YESHORIM, BY THE NUMBERS
In the past three months: April – June 2026
- 13,403 individuals were screened for pre-marital genetic testing.
- 15,486 potential couples (30,972 individuals) called the hotline to request a
compatibility check. - 285 compatibility requests resulted in ‘incompatible’, and genetic counseling was
offered to those individuals and their families (see chart below). - 654 specialized tests were administered for families with rare genetic diseases.
- 112 new families suffering from yet-to-be-identified genetic diseases reached out to Dor
Yeshorim for assistance. Dor Yeshorim is working to meet their needs.
The 285 incompatible results saved families from the following genetic diseases:
| Standard Panel | |
| Aicardi-Goutières Syndrome Type 5 (SAMHD1-Related) | 3 |
| Canavan Disease (ASPA-Related) | 7 |
| Cerebellar Ataxia with Developmental Delay (THG1L-Related) | 3 |
| Congenital Heart Defects and Other Structural Anomalies (GDF1-Related) | 4 |
| Congenital Diarrheal Disorder (DGAT1-Related) | 1 |
| Cystic Fibrosis (CFTR-Related) | 40 |
| Dermatosparaxis Ehlers-Danlos Syndrome (ADAMTS2-Related) | 2 |
| Dihydrolipoamide Dehydrogenase Deficiency (Lipoamide Dehydrogenase Deficiency) | 7 |
| Dyskeratosis Congenita, Autosomal Recessive Type 5 (RTEL1-Related) | 1 |
| MEPAN Syndrome (Mitochondrial Enoyl-CoA Reductase Protein-Associated Neurodegeneration) | 1 |
| Familial Dysautonomia (Riley-Day Syndrome, ELP1-Related) | 20 |
| Fanconi Anemia Complementation Group C (FANCC) | 2 |
| Classic Galactosemia (GALT-Related) | 1 |
| Glycogen Storage Disease Type Ia (von Gierke Disease) | 4 |
| Glycogen Storage Disease Type III (Debranching Enzyme Deficiency) | 1 |
| Familial Hyperinsulinism (Congenital Hyperinsulinism, ABCC8-Related) | 3 |
| Hypomyelinating Leukodystrophy (VPS11-Related) | 1 |
| Joubert Syndrome Type 2 (TMEM216-Related) | 1 |
| Hypomyelinating Leukodystrophy Type 13 (HIKESHI-Related) | 2 |
| Mucolipidosis Type IV (MCOLN1-Related) | 4 |
| Nemaline Myopathy Type 2 (NEB-Related) | 3 |
| Niemann-Pick Disease Type A/B (SMPD1-Related) | 3 |
| Autosomal Recessive Polycystic Kidney Disease (ARPKD, PKHD1-Related) | 3 |
| Retinitis Pigmentosa 28 (FAM161A-Related) | 1 |
| Retinitis Pigmentosa 59 (DHDDS-Related) | 4 |
| Rothmund-Thomson Syndrome (RECQL4-Related) | 1 |
| Smith-Lemli-Opitz Syndrome (DHCR7-Related) | 7 |
| Spastic Tetraplegia, Thin Corpus Callosum, and Progressive Microcephaly (SLC1A4-Related) | 2 |
| Spinal Muscular Atrophy | 7 |
| Tay-Sachs Disease (HEXA-Related) | 22 |
| Tyrosinemia Type 1 (Fumarylacetoacetase Deficiency) | 1 |
| Ventriculomegaly with Cystic Kidney Disease (CRB2-Related) | 5 |
| Walker-Warburg Syndrome (FKTN-Related) | 3 |
| Warsaw Breakage Syndrome (DDX11-Related) | 7 |
| Wilson Disease (ATP7B-Related) | 7 |
| Wolfram Syndrome 1 | 6 |
| Zellweger Spectrum Disorder (PEX2-Related) | 1 |
| 3MC Syndrome (COLEC10-Related) | 2 |
| Hearing Loss Panel | |
| Autosomal Recessive Nonsyndromic Hearing Loss (DFNB1/GJB2) | 56 |
| Autosomal Recessive Nonsyndromic Hearing Loss (DFNB77/LOXHD1) | 1 |
| Autosomal Recessive Nonsyndromic Hearing Loss (DFNB3/MYO15A) | 2 |
| Autosomal Recessive Nonsyndromic Hearing Loss (DFNB9/OTOF) | 1 |
| Perrault Syndrome Type 4 (LARS2-Related) | 1 |
| Pendred Syndrome (SLC26A4-Related) | 1 |
| Neurodevelopmental Disorder with Hearing Loss (SPATA5L1-Related) | 5 |
| Autosomal Recessive Nonsyndromic Hearing Loss (DFNB16/STRC) | 6 |
| Usher Syndrome Type 1C (USH1C-Related) | 2 |
| Specialized Testing * | |
| Achromatopsia Type 2 (CNGA3-Related) | 2 |
| Adrenal Hyperplasia Congenital 21-Hydroxylase Deficiency | 1 |
| Albinism (OCA2) | 1 |
| Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) | 1 |
| Cerebrotendinous Xanthomatosis (CYP27A1-Related) | 1 |
| Congenital Stationary Night Blindness Type 1C (TRPM1-Related) | 1 |
| Fanconi Anemia Complementation Group A (FANCA) | 1 |
| Gaucher Disease | 7 |
| Intellectual Disability and Behavioral Delay (SGSM3-Related) | 1 |
| Stargardts Disease Type 1 | 1 |
| Total | 285 |
*These tests are not yet included in the standard testing panel. They were requested by families currently suffering from the aforementioned diseases to assist with shidduchim and prevent the birth of children with these diseases.
Further funding will allow the standard testing panel to include more of these debilitating diseases.
Statistically Speaking:
210 incompatible matches for debilitating diseases = 420 individuals translates into 210 men and 210 women who will Be”H not face the heartache of children born with recessive, debilitating genetic diseases.
75 incompatibles for Hearing Loss = 150 individuals
This translates into 75 men and 75 women being informed that they face the possibility of
children born with hearing loss.
